News

COVID-19: Potential Vaccines and Logistics

While pharmaceuticals contribute to approximately 2% of annual air cargo volume, the industry transports over one trillion dollars’ worth of cargo every year (IATA). Pharmaceutical shipments have an overwhelmingly large impact on the global response to infectious diseases and general healthcare.

COVID-19 has shown that effective healthcare logistics management requires not only regulatory expertise and extensive planning, but also a proactive global network of logistics experts who can respond to last-minute changes, namely flight cancellations and lockdowns.

CRISPR-based screening technology platform to address critical gaps in target ID and validation

Single cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight

Inventive use of space allows Diagnostics for the Real World to keep on top of demand for COVID-19 test kits

Chesterford Research Park management team and Diagnostics for the Real World work together, re-purposing space to create efficient assembly line

£2.5m of Government funding to accelerate delivery of Incubator at Discovery Park

Science Park helping to drive local economic growth with SELEP support

Richmond Research Institute – COVID-19 Response & Community Testing

Situation:

The coronavirus (COVID-19) pandemic has presented an enormous challenge to individuals and organisations worldwide. Adapting to living with the threat of the SARS-CoV-2 virus among our communities has required significant changes in how we behave and operate.

Our position:

Sequence, the latest Life Sciences newsletter from Mills & Reeve

Where next for UK life sciences regulation?, Where next for the EU’s pharmaceutical strategy? International data transfers after the demise of the US Privacy Shield, Supply chain resilience, and much more…..

Sequence - July 2020 - Issue 11

Almirall calls for collaborative innovation to advance new treatments for skin diseases

- AlmirallShare launches its fifth call for proposals, aiming to establish partnerships to find new assets—new chemical entities, biologics and other advanced therapies—for the treatment of dermatological conditions

- Scientists can participate until October 31, 2020

- AlmirallShare is responsible for 50% of the private-public collaborations at Almirall. This open innovation platform has received more than 350 proposals since its launch in 2017

July 2020 eNews

Click here to view the July edition of eNews.

End-to-End Services for Exosome Research

AMSBIO offers a comprehensive range of end-to-end services for exosome purification, characterization, and engineering.

Biocair expands US presence and capacity

With the expansion of two of Biocair’s North American facilities, the company’s offerings in the US have increased substantially.

The Philadelphia office has doubled in size, with a state-of-the-art cryogenic filling station to further support cell and gene therapy clients, while the expanded Boston office will allow Biocair to improve delivery and service, with greater operational capacity.

My Account